Breaking News

PAREXEL Names Chief Scientific Officer

May 28, 2014

Pretorius to lead clinical research methodologies

Dr. Sy Pretorius has been appointed chief scientific officer at PAREXEL, in addition to his current role as the company's corporate vice president and worldwide head of Early Phase.
Dr. Pretorius will lead innovation efforts for clinical research methodologies and help further integrate the company’s drug development services. He will focus on clinical trial modeling and simulations, adaptive trial designs, and will lead the company's study optimization services by aligning its scientific and therapeutic expertise to provide guidance to customers in clinical study design.
Dr. Pretorius has been with PAREXEL for 18 years, holding positions of increasing responsibility, most recently as head of Early Phase services. He will continue to lead global Phase I and IIa services, which spans three continents, as well as its global Proof of Concept division.
"Customers are increasingly seeking a full spectrum of integrated clinical research services from a single provider to make drug development more efficient," said Mark A. Goldberg, M.D., president and chief operating officer, PAREXEL. "To help us meet these requirements, we have not only recently added new senior leadership to our ranks, but we have expanded the role of one of our current executives. Sy Pretorius has enjoyed a long and distinguished career at the Company, and applying his expertise more broadly will benefit customers and PAREXEL alike."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016